Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 35 |
| List of Tables | 31 | 5 |
| List of Figures | 36 | 1 |
| Introduction | 37 | 1 |
| Global Markets Direct Report Coverage | 37 | 1 |
| B-Cell Non-Hodgkin Lymphoma Overview | 38 | 1 |
| Therapeutics Development | 39 | 2 |
| Pipeline Products for B-Cell Non-Hodgkin Lymphoma Overview | 39 | 1 |
| Pipeline Products for B-Cell Non-Hodgkin Lymphoma Comparative Analysis | 40 | 1 |
| B-Cell Non-Hodgkin Lymphoma Therapeutics under Development by Companies | 41 | 11 |
| B-Cell Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes | 52 | 2 |
| B-Cell Non-Hodgkin Lymphoma Pipeline Products Glance | 54 | 4 |
| Late Stage Products | 54 | 1 |
| Clinical Stage Products | 55 | 1 |
| Early Stage Products | 56 | 1 |
| Unknown Stage Products | 57 | 1 |
| B-Cell Non-Hodgkin Lymphoma Products under Development by Companies | 58 | 30 |
| B-Cell Non-Hodgkin Lymphoma Products under Investigation by Universities/Institutes | 88 | 2 |
| B-Cell Non-Hodgkin Lymphoma Companies Involved in Therapeutics Development | 90 | 129 |
| 3SBio Inc. | 90 | 1 |
| AB Science SA | 91 | 1 |
| AbbVie Inc | 92 | 1 |
| Acetylon Pharmaceuticals, Inc. | 93 | 1 |
| Actinium Pharmaceuticals, Inc. | 94 | 1 |
| ADC Therapeutics Sarl | 95 | 1 |
| Affimed GmbH | 96 | 1 |
| Altor BioScience Corporation | 97 | 1 |
| Amgen Inc. | 98 | 1 |
| arGEN-X BV | 99 | 1 |
| Ariad Pharmaceuticals, Inc. | 100 | 1 |
| Arrien Pharmaceuticals, LLC | 101 | 1 |
| Arvinas, Inc. | 102 | 1 |
| Asana BioSciences, LLC | 103 | 1 |
| Astellas Pharma Inc. | 104 | 1 |
| Astex Pharmaceuticals, Inc. | 105 | 1 |
| AstraZeneca Plc | 106 | 1 |
| Aurigene Discovery Technologies Limited | 107 | 1 |
| Bayer AG | 108 | 1 |
| BeiGene, Ltd. | 109 | 1 |
| Bio-Path Holdings, Inc. | 110 | 1 |
| Biocon Limited | 111 | 1 |
| Biogen Inc | 112 | 1 |
| Biogenomics Limited | 113 | 1 |
| BioInvent International AB | 114 | 1 |
| BioNTech AG | 115 | 1 |
| Biothera Pharmaceutical Inc | 116 | 1 |
| bluebird bio, Inc. | 117 | 1 |
| Boehringer Ingelheim GmbH | 118 | 1 |
| Bristol-Myers Squibb Company | 119 | 1 |
| Calithera Biosciences, Inc. | 120 | 1 |
| Celgene Corporation | 121 | 1 |
| Cell Medica Limited | 122 | 1 |
| Cell>Point, L.L.C. | 123 | 1 |
| Celldex Therapeutics, Inc. | 124 | 1 |
| Celltrion, Inc. | 125 | 1 |
| Cellular Biomedicine Group, Inc. | 126 | 1 |
| Clevexel Pharma SA | 127 | 1 |
| Coherus BioSciences, Inc. | 128 | 1 |
| Constellation Pharmaceuticals, Inc. | 129 | 1 |
| Cornerstone Pharmaceuticals, Inc. | 130 | 1 |
| CrystalGenomics, Inc. | 131 | 1 |
| CSPC Pharmaceutical Group Limited | 132 | 1 |
| CTI BioPharma Corp. | 133 | 1 |
| Curis, Inc. | 134 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 135 | 1 |
| Dynavax Technologies Corporation | 136 | 1 |
| eFFECTOR Therapeutics, Inc. | 137 | 1 |
| Eisai Co., Ltd. | 138 | 1 |
| Eli Lilly and Company | 139 | 1 |
| EpiZyme, Inc. | 140 | 1 |
| Erytech Pharma SA | 141 | 1 |
| Evotec AG | 142 | 1 |
| F. Hoffmann-La Roche Ltd. | 143 | 1 |
| Genentech, Inc. | 144 | 1 |
| Genor BioPharma Co Ltd | 145 | 1 |
| Genosco | 146 | 1 |
| Gilead Sciences, Inc. | 147 | 1 |
| GlaxoSmithKline Plc | 148 | 1 |
| H3 Biomedicine Inc. | 149 | 1 |
| Hutchison MediPharma Limited | 150 | 1 |
| IGF Oncology, LLC. | 151 | 1 |
| Immune Design Corp. | 152 | 1 |
| ImmunoGen, Inc. | 153 | 1 |
| Immunomedics, Inc. | 154 | 1 |
| Immunovaccine, Inc. | 155 | 1 |
| Incyte Corporation | 156 | 1 |
| Infinity Pharmaceuticals, Inc. | 157 | 1 |
| Inflection Biosciences Limited | 158 | 1 |
| Innovent Biologics, Inc. | 159 | 1 |
| JHL Biotech, Inc. | 160 | 1 |
| Johnson &Johnson | 161 | 1 |
| Juno Therapeutics Inc. | 162 | 1 |
| Karyopharm Therapeutics, Inc. | 163 | 1 |
| Kite Pharma Inc | 164 | 1 |
| LFB S.A. | 165 | 1 |
| Mabion SA | 166 | 1 |
| mAbxience S.A. | 167 | 1 |
| MacroGenics, Inc. | 168 | 1 |
| MedImmune, LLC | 169 | 1 |
| Medivation, Inc. | 170 | 1 |
| MEI Pharma, Inc. | 171 | 1 |
| Merck &Co., Inc. | 172 | 1 |
| Merck KGaA | 173 | 1 |
| Millennium Pharmaceuticals Inc | 174 | 1 |
| Mirati Therapeutics Inc. | 175 | 1 |
| Molecular Templates Inc. | 176 | 1 |
| Molplex Ltd. | 177 | 1 |
| MorphoSys AG | 178 | 1 |
| Neumedicines Inc. | 179 | 1 |
| Nimbus Therapeutics, LLC | 180 | 1 |
| Nordic Nanovector ASA | 181 | 1 |
| Novartis AG | 182 | 1 |
| NovImmune SA | 183 | 1 |
| Onconova Therapeutics, Inc. | 184 | 1 |
| Oncternal Therapeutics, Inc. | 185 | 1 |
| Ono Pharmaceutical Co., Ltd. | 186 | 1 |
| OXIS International, Inc. | 187 | 1 |
| Patrys Limited | 188 | 1 |
| Pfizer Inc. | 189 | 1 |
| Pharmacyclics, Inc. | 190 | 1 |
| Philogen S.p.A. | 191 | 1 |
| Portola Pharmaceuticals, Inc. | 192 | 1 |
| RedHill Biopharma Ltd. | 193 | 1 |
| Regeneron Pharmaceuticals Inc | 194 | 1 |
| Respiratorius AB | 195 | 1 |
| Rhizen Pharmaceuticals S.A. | 196 | 1 |
| Sandoz International GmbH | 197 | 1 |
| Sanofi | 198 | 1 |
| Seattle Genetics, Inc. | 199 | 1 |
| Selvita S.A. | 200 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 201 | 1 |
| Sigma-Tau S.p.A. | 202 | 1 |
| Simcere Pharmaceutical Group | 203 | 1 |
| Spectrum Pharmaceuticals, Inc. | 204 | 1 |
| Stemline Therapeutics, Inc. | 205 | 1 |
| Sutro Biopharma, Inc. | 206 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 207 | 1 |
| Takara Bio Inc. | 208 | 1 |
| Takeda Pharmaceutical Company Limited | 209 | 1 |
| TG Therapeutics, Inc. | 210 | 1 |
| The International Biotechnology Center (IBC) Generium | 211 | 1 |
| Theravectys SA | 212 | 1 |
| TRACON Pharmaceuticals Inc | 213 | 1 |
| Transgene SA | 214 | 1 |
| United BioPharma, Inc. | 215 | 1 |
| Unum Therapeutics, Inc. | 216 | 1 |
| Vivolux AB | 217 | 1 |
| Xenetic Biosciences (UK) Limited | 218 | 1 |
| B-Cell Non-Hodgkin Lymphoma Therapeutics Assessment | 219 | 38 |
| Assessment by Monotherapy Products | 219 | 1 |
| Assessment by Combination Products | 220 | 1 |
| Assessment by Target | 221 | 17 |
| Assessment by Mechanism of Action | 238 | 15 |
| Assessment by Route of Administration | 253 | 2 |
| Assessment by Molecule Type | 255 | 2 |
| Drug Profiles | 257 | 813 |
| (decitabine + tetrahydrouridine) Drug Profile | 257 | 1 |
| (dezapelisib + itacitinib adipate) Drug Profile | 258 | 1 |
| 13197 Drug Profile | 259 | 2 |
| 187Re-EC-G Drug Profile | 261 | 1 |
| 19-3s Drug Profile | 262 | 1 |
| 20-3s Drug Profile | 263 | 1 |
| 202-b Drug Profile | 264 | 2 |
| 765IGF-MTX Drug Profile | 266 | 1 |
| AB-8779 Drug Profile | 267 | 1 |
| ABC-294640 Drug Profile | 268 | 5 |
| abexinostat hydrochloride Drug Profile | 273 | 2 |
| acalabrutinib Drug Profile | 275 | 3 |
| ACY-775 Drug Profile | 278 | 1 |
| ADCT-402 Drug Profile | 279 | 2 |
| ADN-MCL Drug Profile | 281 | 1 |
| AFM-11 Drug Profile | 282 | 1 |
| AFM-13 Drug Profile | 283 | 4 |
| alisertib Drug Profile | 287 | 5 |
| ALT-803 Drug Profile | 292 | 3 |
| AMG-319 Drug Profile | 295 | 1 |
| ARGX-110 Drug Profile | 296 | 4 |
| ARN-3261 Drug Profile | 300 | 1 |
| ARV-771 Drug Profile | 301 | 1 |
| ARV-825 Drug Profile | 302 | 1 |
| ASN-002 Drug Profile | 303 | 1 |
| asparaginase Drug Profile | 304 | 7 |
| AT-7519 Drug Profile | 311 | 3 |
| atezolizumab Drug Profile | 314 | 14 |
| avicin d Drug Profile | 328 | 1 |
| azacitidine Drug Profile | 329 | 5 |
| AZD-3965 Drug Profile | 334 | 2 |
| AZD-9150 Drug Profile | 336 | 2 |
| baltaleucel-T Drug Profile | 338 | 2 |
| BAY-1143572 Drug Profile | 340 | 1 |
| BB-001 Drug Profile | 341 | 1 |
| bb-2121 Drug Profile | 342 | 2 |
| BC-8Y90 Drug Profile | 344 | 1 |
| bendamustine hydrochloride Drug Profile | 345 | 3 |
| bendamustine hydrochloride Drug Profile | 348 | 1 |
| Betalutin Drug Profile | 349 | 5 |
| BGB-3111 Drug Profile | 354 | 2 |
| BI-1206 Drug Profile | 356 | 2 |
| BI-836826 Drug Profile | 358 | 1 |
| birabresib Drug Profile | 359 | 2 |
| blinatumomab Drug Profile | 361 | 8 |
| BLyS-gel Drug Profile | 369 | 1 |
| BMS-986016 Drug Profile | 370 | 2 |
| bortezomib Drug Profile | 372 | 8 |
| BP-1002 Drug Profile | 380 | 1 |
| brentuximab vedotin Drug Profile | 381 | 24 |
| brigatinib Drug Profile | 405 | 10 |
| BTH-1677 Drug Profile | 415 | 12 |
| BTM-10XX Drug Profile | 427 | 1 |
| buparlisib hydrochloride Drug Profile | 428 | 5 |
| BVX-20 Drug Profile | 433 | 1 |
| C-15231A Drug Profile | 434 | 1 |
| CA-4948 Drug Profile | 435 | 2 |
| carfilzomib Drug Profile | 437 | 12 |
| CB-839 Drug Profile | 449 | 7 |
| CBM-C19.1 Drug Profile | 456 | 1 |
| CBM-C20.1 Drug Profile | 457 | 2 |
| CC-122 Drug Profile | 459 | 2 |
| CC-223 Drug Profile | 461 | 1 |
| CC-90011 Drug Profile | 462 | 1 |
| CDX-301 Drug Profile | 463 | 4 |
| Cellular Immunotherapy for Oncology Drug Profile | 467 | 1 |
| Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia Drug Profile | 468 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma Drug Profile | 469 | 1 |
| Cellular Immunotherapy to Target CD19 for ALL Drug Profile | 470 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Leukemias and B-Cell Lymphomas Drug Profile | 471 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile | 472 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Non-Hodgkin Lymphoma Drug Profile | 473 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 474 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 475 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 476 | 1 |
| Cellular Immunotherapy to Target CD20 for B-Cell Leukemia and Lymphoma Drug Profile | 477 | 1 |
| Cellular Immunotherapy to Target CD30 for Oncology Drug Profile | 478 | 1 |
| Cellular Immunotherapy to Target CD38 for cancer Drug Profile | 479 | 1 |
| Cellular Immunotherapy to Target GM-CSF for Oncology Drug Profile | 480 | 1 |
| cerdulatinib Drug Profile | 481 | 3 |
| CG-026806 Drug Profile | 484 | 1 |
| ChiLob-7/4 Drug Profile | 485 | 2 |
| citarinostat Drug Profile | 487 | 2 |
| copanlisib hydrochloride Drug Profile | 489 | 4 |
| CPI-0610 Drug Profile | 493 | 2 |
| CPI-169 Drug Profile | 495 | 1 |
| CPI-613 Drug Profile | 496 | 5 |
| CUDC-907 Drug Profile | 501 | 4 |
| CVXL-0074 Drug Profile | 505 | 1 |
| CYC-065 Drug Profile | 506 | 3 |
| daratumumab Drug Profile | 509 | 12 |
| Darleukin Drug Profile | 521 | 2 |
| dasiprotimut-T Drug Profile | 523 | 5 |
| DCDS-0780A Drug Profile | 528 | 1 |